Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Texas medication algorithm project: clinical results for schizophrenia.

Alexander L Miller1, M Lynn Crismon, A John Rush

  • 1Department of Psychiatry, MS 7792, University of Texas Health Science Center at San Antionio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA. millera@uthscsa.edu

Schizophrenia Bulletin
|January 6, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Vagus Nerve Stimulation on Suicidal Ideation in Markedly Treatment-Resistant Major Depression: A RECOVER Study Report.

The Journal of clinical psychiatry·2026
Same author

The Use of Vagus Nerve Stimulation (VNS) in the Management of Patients with Difficult-to-Treat Major Depressive Disorder (MDD): An Expert Consensus Statement.

Neuropsychiatric disease and treatment·2026
Same author

Is It Time for a Universal Outcome Measure to Deliver on the Promises of Interventional Psychiatry?

The American journal of psychiatry·2026
Same author

Derivation of an updated brief multivariable prediction model to detect panic-related anxiety in emergency department patients with cardiopulmonary complaints.

Frontiers in psychiatry·2026
Same author

Assessing symptom severity in patients with markedly treatment-resistant depression: Insights from the RECOVER trial.

Journal of affective disorders·2026
Same author

Factors associated with interpersonal retraumatization in children and adolescents: A prospective study.

Psychiatry research·2025

Algorithm-guided treatment (ALGO) showed initial symptom improvement and sustained cognitive gains in schizophrenia patients compared to treatment as usual (TAU). However, TAU patients eventually achieved similar symptom levels over 12 months.

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Health Services Research

Background:

  • The Texas Medication Algorithm Project (TMAP) aimed to improve psychiatric care through standardized treatment protocols.
  • Algorithm-guided treatment (ALGO) interventions incorporate clinical coordinators and patient education.
  • Previous studies highlighted the potential of algorithms in managing mental health conditions.

Purpose of the Study:

  • To compare the effectiveness of algorithm-guided treatment (ALGO) versus treatment as usual (TAU) for schizophrenia patients within the TMAP framework.
  • To assess the impact of ALGO on symptom severity and cognitive functioning.
  • To evaluate secondary outcomes in patients receiving algorithms for other mood disorders.

Main Methods:

  • A comparative study involving three groups of patients: ALGO for schizophrenia (n=165), TAU for schizophrenia (n=144), and a mixed-disorder algorithm group (n=156).

Related Experiment Videos

  • Symptom severity was measured using the Brief Psychiatric Rating Scale.
  • Cognitive functions were assessed at multiple time points throughout the 12-month study period.

    • Main Results:

    • The ALGO group demonstrated modestly greater symptom improvement in the first quarter compared to TAU.
    • Cognitive functions showed significantly greater improvement in the ALGO group at 3 and 9 months.
    • While TAU patients' symptom levels improved over time, catching up to the ALGO group by 12 months, sustained cognitive benefits favored ALGO.
    • Secondary comparisons with a different TAU group also indicated superior cognitive improvements with ALGO.

    Conclusions:

    • Algorithm-guided treatment in TMAP offers initial advantages in symptom reduction and more pronounced, sustained improvements in cognitive functioning for schizophrenia patients.
    • While TAU can lead to symptom recovery over a longer period, ALGO may provide distinct benefits for cognitive health.
    • The findings support the integration of algorithm-guided interventions, particularly for enhancing cognitive outcomes in psychiatric care.